ROCKAWAY, N.J., July 23, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the second quarter ended June 30, 2025, after the close of the market on Wednesday, August 6, 2025.
Management will host a webinar at 4:30 PM EDT to review the financial results and answer questions. Investors can access the webinar using the details below:
Wednesday, August 6, 4:30 PM EDT
Dial-In: (646) 931-3860
Webinar ID: 843 8084 9004
Passcode: 049555
Registration Link: Click here to participate and ask questions on the call.
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products to treat chronic pain syndromes through non-invasive neuromodulation technology are gammaCore non-invasive vagus nerve stimulation (nVNS) and Quell neurostimulator. Additionally, the company commercializes its Truvaga products, handheld, and personal use nVNS products utilizing bioelectronic technologies, to promote general wellness and human performance.
For more information, visit www.electrocore.com.
Contact
ECOR Investor Relations
(973) 302-9253
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$5.04 |
| Daily Change: | 0.14 2.86 |
| Daily Volume: | 32,543 |
| Market Cap: | US$40.320M |
September 30, 2025 September 29, 2025 September 05, 2025 September 03, 2025 August 06, 2025 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
